AR108792A1 - Composiciones que comprenden timolol - Google Patents
Composiciones que comprenden timololInfo
- Publication number
- AR108792A1 AR108792A1 ARP170101655A ARP170101655A AR108792A1 AR 108792 A1 AR108792 A1 AR 108792A1 AR P170101655 A ARP170101655 A AR P170101655A AR P170101655 A ARP170101655 A AR P170101655A AR 108792 A1 AR108792 A1 AR 108792A1
- Authority
- AR
- Argentina
- Prior art keywords
- timolol
- pharmaceutically acceptable
- rosacea
- acceptable salt
- treatment
- Prior art date
Links
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 title abstract 7
- 229960004605 timolol Drugs 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001303601 Rosacea Species 0.000 abstract 4
- 201000004700 rosacea Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960005221 timolol maleate Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382278 | 2016-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108792A1 true AR108792A1 (es) | 2018-09-26 |
Family
ID=56203291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101655A AR108792A1 (es) | 2016-06-16 | 2017-06-15 | Composiciones que comprenden timolol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210220368A1 (ja) |
| EP (1) | EP3471731A1 (ja) |
| JP (1) | JP2019518039A (ja) |
| KR (1) | KR20190017801A (ja) |
| CN (1) | CN109475561A (ja) |
| AR (1) | AR108792A1 (ja) |
| AU (1) | AU2017285256A1 (ja) |
| BR (1) | BR112018076014A2 (ja) |
| CA (1) | CA3026974A1 (ja) |
| EA (1) | EA201990041A1 (ja) |
| MA (1) | MA45378A (ja) |
| MX (1) | MX2018015240A (ja) |
| TW (1) | TW201803568A (ja) |
| WO (1) | WO2017216307A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118453616A (zh) * | 2022-08-01 | 2024-08-09 | 北京梅尔森医药技术开发有限公司 | 一种治疗敏感肌肤的外用制剂及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866567A1 (fr) * | 2004-02-20 | 2005-08-26 | Galderma Res & Dev | Utilisation d'un antagoniste du recepteur beta-adrenergique, at1, 5-ht2, 5-ht5 et/ou de la galanine, pour le traitement de la rosacee |
| WO2007011972A2 (en) * | 2005-07-19 | 2007-01-25 | Inverseon, Inc. | Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases |
| FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
-
2017
- 2017-06-15 US US16/309,808 patent/US20210220368A1/en not_active Abandoned
- 2017-06-15 EP EP17729880.9A patent/EP3471731A1/en not_active Withdrawn
- 2017-06-15 BR BR112018076014-5A patent/BR112018076014A2/pt not_active Application Discontinuation
- 2017-06-15 MA MA045378A patent/MA45378A/fr unknown
- 2017-06-15 MX MX2018015240A patent/MX2018015240A/es unknown
- 2017-06-15 JP JP2018565309A patent/JP2019518039A/ja active Pending
- 2017-06-15 CN CN201780042807.3A patent/CN109475561A/zh active Pending
- 2017-06-15 KR KR1020187036463A patent/KR20190017801A/ko not_active Withdrawn
- 2017-06-15 WO PCT/EP2017/064704 patent/WO2017216307A1/en not_active Ceased
- 2017-06-15 AU AU2017285256A patent/AU2017285256A1/en not_active Abandoned
- 2017-06-15 CA CA3026974A patent/CA3026974A1/en not_active Abandoned
- 2017-06-15 EA EA201990041A patent/EA201990041A1/ru unknown
- 2017-06-15 AR ARP170101655A patent/AR108792A1/es unknown
- 2017-06-16 TW TW106120188A patent/TW201803568A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475561A (zh) | 2019-03-15 |
| TW201803568A (zh) | 2018-02-01 |
| CA3026974A1 (en) | 2017-12-21 |
| BR112018076014A2 (pt) | 2019-03-26 |
| JP2019518039A (ja) | 2019-06-27 |
| EA201990041A1 (ru) | 2019-05-31 |
| MA45378A (fr) | 2019-04-24 |
| MX2018015240A (es) | 2019-04-15 |
| WO2017216307A1 (en) | 2017-12-21 |
| AU2017285256A1 (en) | 2019-01-24 |
| US20210220368A1 (en) | 2021-07-22 |
| KR20190017801A (ko) | 2019-02-20 |
| EP3471731A1 (en) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2019011606A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CO2018004206A2 (es) | Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d” | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |